Telomir-Zn Shows Growth Inhibition in Human and Canine Osteosarcoma Models

Telomir Pharmaceuticals (NASDAQ: TELO) has announced new research findings from The Ohio State University College of Veterinary Medicine showing that its lead compound, Telomir-Zn, produced growth inhibition across human and canine osteosarcoma cell-line models at similar low drug concentrations. The study, led by Shay Bracha, DVM, MS, DACVIM (Oncology), evaluated Telomir-Zn in one human and two canine osteosarcoma models. These results support further translational investigation and a potential development pathway using naturally occurring canine osteosarcoma, a disease that shares many biological and clinical features with human osteosarcoma.

The significance of these findings lies in the potential to leverage canine osteosarcoma as a translational model for human osteosarcoma. Canine osteosarcoma occurs naturally in dogs and progresses in a manner similar to human osteosarcoma, making it a valuable tool for evaluating novel therapies. If Telomir-Zn demonstrates efficacy in canine osteosarcoma, it could provide a faster and more cost-effective route to assess its potential in human patients. Telomir is in discussions with The Ohio State University College of Veterinary Medicine and is assessing next steps for a potential in vivo efficacy study in canine osteosarcoma. Such a study could support both veterinary development and translational advancement toward human osteosarcoma, addressing a significant unmet need in both veterinary and human oncology.

Osteosarcoma is an aggressive bone cancer that affects both humans and dogs, with limited treatment options and poor outcomes in advanced cases. The ability of Telomir-Zn to inhibit growth in both human and canine cell lines at similar low concentrations suggests a shared mechanism of action that could be relevant across species. This cross-species activity is particularly promising because it may streamline the drug development process, allowing researchers to gather efficacy and safety data in a naturally occurring disease model that more closely mirrors human disease than traditional animal models.

While the osteosarcoma findings are encouraging, Telomir’s immediate focus remains its triple-negative breast cancer (TNBC) program. The company is advancing toward site initiation and Phase 1/2 patient enrollment under an active FDA-cleared Investigational New Drug (IND) application for advanced or metastatic TNBC. Telomir-Zn is designed to modulate intracellular metal homeostasis and epigenetic regulation, targeting epigenetic and metabolic pathways implicated in cancer. The FDA clearance for the TNBC trial underscores the potential of Telomir-Zn as a novel therapeutic approach.

For investors and the broader biotechnology community, these results highlight Telomir’s commitment to exploring multiple oncology indications for Telomir-Zn. The osteosarcoma data not only expand the potential applications of the compound but also demonstrate the company’s strategy of using translational models to accelerate development. To view the full press release, visit https://nnw.fm/laeGH. The latest news and updates relating to TELO are available in the company’s newsroom at https://nnw.fm/TELO.